Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) AND ANBENITAMAB (KN026) GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE FIRS

VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) AND ANBENITAMAB (KN026) GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE FIRS

July 14, 2026

a260714_00.png

Previous: VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE TREATMENT OF PLATINUM-RESISTANT ADVANCED OVARIAN CANCER, PRIMARY PERITONEAL CANCER, AND FAL

Next: VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2070 INJECTION FOR THE TREATMENT OF MIXED HYPERLIPIDAEMIA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHI

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat